Please Wait
Applying Filters...
menu
    • menu
    Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

    Data Compilation
    #PharmaFlow

    Pipeline Prospector October 2025: Novartis to buy Avidity for US$ 12 bn; FDA approves Bayer’s med to treat hot flashes

    Stock Recap
    #PipelineProspector

    Menu

    Remimazolam Besylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 43,980Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name Registration No. Compound Registration Date Manufacturer Manufacturer's Country Manufacturer's Address
    31/10/2025 Cambrex Corporation
    U.S.A
    		 Samoh Pharmaceutical Co., Ltd. Su0106-1-ND Remimazolam besylate 2021-01-07 Cambrex, Karlskoga AB Sweden Bjorkborn Industriomrade Karlskoga, 691 85 Sweden